Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume3
DOIs
StatePublished - 2016

Fingerprint

Lewy Bodies
Lewy Body Disease
Sphingolipids
Autopsy
Alzheimer Disease
Pathology
Dementia
Lipids
Ceramides
Fatty Acids
Phenotype

Keywords

  • Alzheimer's disease
  • Autopsy
  • Ceramide
  • Lewy body
  • Lipids

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

@article{9dd884cced2443eaa5fe9fd40ed41971,
title = "Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology",
abstract = "Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.",
keywords = "Alzheimer's disease, Autopsy, Ceramide, Lewy body, Lipids",
author = "Rodolfo Savica and Murray, {Melissa E} and Persson, {Xuan Mai} and Kantarci, {Kejal M} and Parisi, {Joseph E} and Dickson, {Dennis W} and Petersen, {Ronald Carl} and Ferman, {Tanis Jill} and Boeve, {Bradley F} and Mielke, {Michelle M}",
year = "2016",
doi = "10.1016/j.dadm.2016.02.005",
language = "English (US)",
volume = "3",
pages = "43--50",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

AU - Savica, Rodolfo

AU - Murray, Melissa E

AU - Persson, Xuan Mai

AU - Kantarci, Kejal M

AU - Parisi, Joseph E

AU - Dickson, Dennis W

AU - Petersen, Ronald Carl

AU - Ferman, Tanis Jill

AU - Boeve, Bradley F

AU - Mielke, Michelle M

PY - 2016

Y1 - 2016

N2 - Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.

AB - Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.

KW - Alzheimer's disease

KW - Autopsy

KW - Ceramide

KW - Lewy body

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=84961626573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961626573&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2016.02.005

DO - 10.1016/j.dadm.2016.02.005

M3 - Article

AN - SCOPUS:84961626573

VL - 3

SP - 43

EP - 50

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -